µÏÍþ¹ú¼Ê

µÏÍþÖƵÏÍþ¹ú¼Ê µÏÍþÖƵÏÍþ¹ú¼Ê

¼ò ¤™
  • ¼ò
  • ·±
  • EN
¤œ
Ïà¹ØÁ´½Ó
  • ½­ËÕºÀÉ­µÏÍþ¹ú¼ÊÒµ¼¯ÍÅÓÐÏÞ¹«Ë¾¥Y
ÐÂÎÅ·¢²¼
Press Release
Ê×Ò³  >  ÐÂÎÅÖÐÐÄ  >  ÐÂÎÅ·¢²¼
ESMO ASIA | µÏÍþÖƵÏÍþ¹ú¼ÊRisvutatug Rezetecan£¨ HS-20093£©ÖÎÁÆNSCLCµÄ¢ñÆÚÑо¿½á¹ûÁÁÏà
·¢²¼ÈÕÆÚ£º2025/12/17
×ÖºÅ

- ÔÚ¾Ö²¿ÍíÆÚ»òתÒÆÐÔ·ÇСϸ°û·Î°©£¨NSCLC£©»¼ÕßÖУ¬Risvutatug Rezetecan¸øµÏÍþ¹ú¼Ê¼ÁÁ¿8.0 ºÍ10.0 mg/kgÿ3ÖÜÒ»´Î£¬±íÏÖ³öÁîÈËÕñ·ÜµÄ¿¹Ö×Áö»îÐÔ£¬ÓÈÆäÊÇÔÚÇý¶¯»ùÒò£¨AGA£©ÒõÐԵķÇÁÛ×´NSCLCÖС£

- Risvutatug RezetecanµÄ°²È«ÐÔ¿É¿Ø£¬·ûºÏÆä×÷ÓûúÖÆ¡£10.0 mg/kg¼ÁÁ¿×éÖСÝ3¼¶TRAEsºÍ¼ÁÁ¿½µµÍµÄ·¢ÉúÂʸßÓÚ8.0 mg/kg¼ÁÁ¿×é¡£

- Risvutatug RezetecanÒÑÔÚÖйú»ñµÃº¬²¬»¯Áƺó½øÕ¹»ò¸´·¢µÄAGAÒõÐÔµÄÍíÆÚ/תÒÆÐÔ·ÇÁÛ×´NSCLCµÄÍ»ÆÆÐÔÁÆ·¨ÈÏÖ¤¡£


½üÈÕ£¬µÏÍþÖƵÏÍþ¹ú¼Ê¼¯ÍÅÓÐÏÞ¹«Ë¾£¨ÒÔϼò³Æ¡°µÏÍþÖƵÏÍþ¹ú¼Ê¡±£¬03692.HK£©×ÔÖ÷Ñз¢µÄB7-H3°ÐÏò¿¹Ìå-µÏÍþ¹ú¼ÊÎïżÁªÎADC£©Risvutatug Rezetecan£¨HS-20093/GSK5764227£©£¬ÔÚ2025ÄêÅ·ÖÞÖ×ÁöÄÚ¿Æѧ»áÑÇÖÞÄê»á£¨ESMO ASIA£©ÉÏÒÔСÐÍ¿ÚÍ·±¨¸æ(Mini Oral)µÄÐÎʽÁÁÏà¡£



ARTEMIS-001ÊÇÒ»ÏîÕë¶ÔÖйú³ÉÄêÍíÆÚʵÌåÁö»¼ÕßµÄIÆÚÁÙ´²Ñо¿£¬·ÖΪ¿ª·Å±êÇ©µÄ¼ÁÁ¿µÝÔö£¨Ia²¿·Ö£©ºÍ¼ÁÁ¿À©Õ¹£¨Ib²¿·Ö£©¡£ÔÚ¸ÃÑо¿ÖУ¬¶ÔÓÚ½ÓÊܱê×¼ÖÎÁƺó²¡Çé½øÕ¹»òÎÞ·¨ÄÍÊܱê×¼ÖÎÁƵķÇСϸ°û·Î°©£¨NSCLC£©»¼Õߣ¬½«½ÓÊÜrisvutatug rezetecanÖÎÁÆ£¬¼ÁÁ¿Îª8.0 mg/kg»ò10.0 mg/kg£¬Ã¿3ÖܸøµÏÍþ¹ú¼Ê1´Î£¬Ö±ÖÁ¼²²¡½øÕ¹¡¢³öÏÖ²»¿ÉÄÍÊܵĶ¾ÐÔ¡¢»¼Õßʧ·Ã»òËÀÍö¡£IaÆÚµÄÖ÷ÒªÖÕµãÊÇMTD/MAD£¬IbÆÚµÄÖ÷ÒªÖÕµãÊÇÑо¿Õ߸ù¾ÝRECIST v1.1±ê×¼ÆÀ¹ÀµÄ¿Í¹Û»º½âÂÊ£¨ORR£©¡£

Ñо¿½á¹ûÏÔʾ£¬ÔÚ¾Ö²¿ÍíÆÚ»òתÒÆÐÔNSCLC»¼ÕßÖУ¬risvutatug rezetecanÕ¹ÏÖ³ö£º

  • ÁîÈËÕñ·ÜµÄ¿¹Ö×Áö»îÐÔ£º¹²167ÀýNSCLC»¼Õß½ÓÊÜrisvutatug rezetecan 8.0 mg/kg»ò10.0 mg/kgÖÎÁÆ£¬ÖÐλËæ·Ãʱ¼äΪ7.85¸öÔ£¬Á½¸ö¼ÁÁ¿×é¾ù¹Û²ìµ½Ã÷È·µÄÁÆЧ£¬AGAÒõÐÔ·ÇÁÛ×´ NSCLC »¼Õß»ñÒæÓÈΪÏÔÖø¡£¸ÃÑÇ×éÖУ¬8.0 mg/kg ×é¾­È·ÈϿ͹ۻº½âÂÊ£¨cORR£©´ï33.3%£¬ÖÐλÎÞ½øÕ¹Éú´æÆÚ£¨mPFS£©7.0 ¸öÔ£¬ÖÐλ×ÜÉú´æÆÚ£¨mOS£©ÉÐδ´ïµ½£»10.0 mg/kg ×é cORR Ϊ 10.7%£¬mPFS 4.1 ¸öÔ£¬mOS 17.5 ¸öÔ¡£ 

  • ¿É¿ØµÄ°²È«ÐÔ£º8.0 mg/kg¼ÁÁ¿×éÖСÝ3¼¶²»Á¼Ê¼þ¡¢µ¼Ö¼ÁÁ¿¼õÉÙºÍÖÎÁÆÖжÏ/Í£µÏÍþ¹ú¼ÊµÄ²»Á¼Ê¼þµÄ·¢ÉúÂʾùµÍÓÚ10mg/kg¼ÁÁ¿×é¡£×î³£¼ûµÄCTCAE¡Ý3¼¶µÄÖÎÁÆÏà¹Ø²»Á¼Ê¼þ£¨TRAEs£©ÊÇѪҺ¶¾ÐÔ¡£8.0 mg/kg¼ÁÁ¿×éÖÐÓÐ2Àý»¼Õߣ¨2.2%£©±¨¸æÁËÓëÖÎÁÆÏà¹ØµÄ1/2¼¶¼äÖÊÐԷβ¡£¨ILD£©£»Î´±¨¸æ¡Ý3¼¶ILD¡£10mg/kg¼ÁÁ¿×éÖÐ䱨¸æILD, δ·¢ÏÖÐµİ²È«Ðźš£


¹ØÓÚRisvutatug Rezetecan

Risvutatug Rezetecan£¨HS-20093/GSK5764227£©ÊǵÏÍþÖƵÏÍþ¹ú¼Ê×ÔÖ÷Ñз¢µÄB7-H3°ÐÏòADC£¬ÓÉÈ«ÈËÔ´µÄB7-H3µ¥¿¹ÓëÍØÆËÒ칹øÒÖÖƼÁ(TOPOi)ÓÐЧÔغɹ²¼ÛÁ¬½Ó¶ø³É¡£½ØÖÁÄ¿Ç°£¬risvutatug rezetecanÖÎÁƸ´·¢ÐÔСϸ°û·Î°©ÒÔ¼°¹ÇÈâÁöÊÊÓ¦Ö¢ÒÑÔÚÖйú½øÈëIIIÆÚÁÙ´²Ñо¿½×¶Î¡£Í¬Ê±£¬risvutatug rezetecanÓÃÓÚÖÎÁÆ·ÇСϸ°û·Î°©¡¢Í·¾±°©¡¢Ç°ÁÐÏÙ°©¡¢Ê³¹ÜÁÛ°©¡¢½áÖ±³¦°©¼°ÆäËûʵÌåÁöµÄ¶àÏîPoC¸ÅÄîÑéÖ¤ÁÙ´²Ñо¿ÕýÔÚ½øÐС£

2023Äê12Ô£¬µÏÍþÖƵÏÍþ¹ú¼ÊÊÚÓè¸ðÀ¼ËØÊ·¿Ë£¨GSK£©¿ª·¢¡¢Éú²ú¼°ÉÌÒµ»¯risvutatug rezetecanÈ«Çò¶ÀÕ¼Ðí¿ÉȨÀû£¨²»º¬Öйú´ó½¡¢Ïã¸Û¡¢°ÄÃż°Ì¨ÍåµØÇø£©¡£Ä¿Ç°¸Ã²úÆ·ÕýÓÉGSKÔÚº£ÍâÍÆÐТñÆں͢óÆÚÁÙ´²ÊÔÑé¡£

½ØÖÁÄ¿Ç°£¬risvutatug rezetecanÒÑ»ñµÃÖйú¹ú¼ÒµÏÍþ¹ú¼Ê¼à¾Ö£¨NMPA£©¡¢Å·ÖÞµÏÍþ¹ú¼ÊÆ·¹ÜÀí¾Ö£¨EMA£©ºÍÃÀ¹úʳµÏÍþ¹ú¼Ê¼à¾Ö£¨FDA£©ÊÚÓèµÄ°ËÏî¼à¹ÜÈ϶¨£¬Õâ³ä·ÖÓ¡Ö¤Á˸òúÆ·ÔÚÖÎÁÆһϵÁÐʵÌåÁö·½ÃæµÄDZÁ¦¡£


¹ØÓÚNSCLC

·Î°©ÈÔÈ»ÊÇÈ«Çò×î³£¼ûºÍÖÂÃüµÄ¶ñÐÔÖ×ÁöÖ®Ò»£¬Ô¼Õ¼ËùÓа©Ö¢Ïà¹ØËÀÍöµÄ18.7%[1]¡£NSCLCÔ¼Õ¼ËùÓзΰ©²¡ÀýµÄ85%£¬Æä·Ö×Ó¸´ÔÓÐÔºÍÒìÖÊÐÔʹÆäÓëÖÚ²»Í¬£¬Õâ¶Ô¿ª·¢ÓÐЧµÄÖÎÁƲßÂÔÌá³öÁ˳ÖÐøµÄÌôÕ½[2]¡£NSCLCÖдóÔ¼70%Ϊ·ÇÁÛ×´NSCLC£¬Ö÷ÒªÓÉÏÙ°©ºÍ´óϸ°û°©×é³É£¬¶øÆäÓà30%Ôò±íÏÖΪÁÛ×´×é֯ѧ[3]¡£°ÐÏòÖÎÁƺÍÃâÒß¼ì²éµãÒÖÖƼÁ£¨ICI£©µÄ³öÏÖ¿ª´´ÁËNSCLCÖÎÁƵıä¸ïʱ´ú¡£°ÐÏòÖÎÁÆ´ó´óÌá¸ßÁËAGAÑôÐÔ»¼ÕßµÄÁÙ´²ÁÆЧ£¬¶øICIÔòΪAGAÒõÐԵĻ¼ÕßÖØж¨ÒåÁËÖÎÁÆÇ°¾°¡£¾¡¹ÜÈ¡µÃÁËÕâЩ·¢Õ¹£¬µ«´ó¶àÊý»¼Õß×îÖÕÈÔÃæÁÙ¼²²¡½øÕ¹£¬ÕâÖ÷ÒªÊÇÓÉÔ­·¢ÐÔ»ò»ñµÃÐÔÄ͵ÏÍþ¹ú¼ÊÐÔËùµ¼Ö£¬´Ó¶øÏÞÖÆÁ˳ÖÐø³¤ÆÚ»ñÒæ¡£

¹ØÓÚESMO ASIA

2025ÄêÅ·ÖÞÖ×ÁöÄÚ¿Æѧ»áÑÇÖÞÄê»á£¨ESMO ASIA£©ÓÉÅ·ÖÞÖ×ÁöÄÚ¿Æѧ»á£¨ESMO£©Ö÷°ì£¬»ã¾ÛÁË×î¾ß¾­ÑéµÄ¹ú¼Êר¼Ò£¬Ìṩ¸ßË®×¼µÄº­¸ÇËùÓÐÖ÷ÒªÖ×ÁöÀàÐ͵ÄÖ×Áöѧ½ÌÓý·½°¸£¬²¢Îª¹ú¼ÊͬÐÐÌṩÖØÒªµÄ½»Á÷»ú»á£¬Ê¹ÑÇÌ«µØÇøµÄÖ×ÁöѧרҵÈËÊ¿Äܹ»Óë¿ìËÙ·¢Õ¹µÄÖ×Áöѧ¿ÆѧÓë½ÌÓý±£³Öͬ²½¡£




²Î¿¼ÎÄÏ×£º

1.Bray, F.; Laversanne, M.; Sung, H., et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2024, 74, 229-263.

2.Chen, Z.; Fillmore, C.M.; Hammerman, P.S.; Kim, C.F.; Wong, K.K. Non-small-cell lung cancers: a heterogeneous set of diseases. Nat Rev Cancer 2014, 14, 535-546.

3. National Cancer Institute. SEER Cancer Statistics Factsheets: Lung and Bronchus Cancer. SEER Cancer Statistics Factsheets: Lung and Bronchus Cancer. October 2023.


¹ØÓÚµÏÍþÖƵÏÍþ¹ú¼Ê

µÏÍþÖƵÏÍþ¹ú¼ÊÊÇÖйúÁìÏȵĴ´ÐÂÇý¶¯ÐÍÖƵÏÍþ¹ú¼ÊÆóÒµ£¬ÏÂÊôºÀÉ­µÏÍþ¹ú¼ÊÒµ¡¢³£Öݺã°îµÏÍþ¹ú¼ÊÒµ¡¢µÏÍþÉúÎïÒ½µÏÍþ¹ú¼ÊµÈ×Ó¹«Ë¾£¬ÒÔ¡¸³ÖÐø´´Ð£¬Ìá¸ßÈËÀàÉúÃüÖÊÁ¿¡¹ÎªÊ¹Ãü£¬Öصã¹Ø×¢¿¹Ö×Áö¡¢¿¹¸ÐȾ¡¢ÖÐÊàÉñ¾­ÏµÍ³¡¢´úл¼°×ÔÉíÃâÒßµÈÖØ´ó¼²²¡ÖÎÁÆÁìÓò¡£½ØÖÁÄ¿Ç°£¬¹«Ë¾ÔÚÖйú²úÉúÏúÊÛÊÕÈëµÄ´´ÐµÏÍþ¹ú¼Ê¹²7¿î£¬ÐγÉÁ˷ḻµÄ²úÆ·¹ÜÏß¡£µÏÍþÖƵÏÍþ¹ú¼ÊÁ¬Ðø¶àÄêλ¾ÓÈ«ÇòÖƵÏÍþ¹ú¼ÊÆóÒµ°ÙÇ¿¡¢ÖйúÒ½µÏÍþ¹ú¼ÊÑз¢²úÆ·Ïß×î¼Ñ¹¤ÒµÆóҵǰ3Ç¿£¬Êǹú¼ÒÖصã¸ßм¼ÊõÆóÒµ¡¢¹ú¼Ò¼¼Êõ´´ÐÂʾ·¶ÆóÒµ¡£µÏÍþÖƵÏÍþ¹ú¼ÊÓÚ2019Äê6ÔÂÔÚÏã¸ÛÁª½»Ëù¹ÒÅÆÉÏÊУ¨¹ÉƱ´úÂ룺03692.HK£©¡£

ÃâÔðÉùÃ÷

±¾ÎĽö¹©Ò½ÁÆÎÀÉúרҵÈËÊ¿²ÎÔÄ£¬·Ç¹ã¸æÓÃ;¡£µÏÍþÖƵÏÍþ¹ú¼Ê²»ÍƼöÈκÎδ»ñÅúµÏÍþ¹ú¼ÊƷʹÓúÍ/»òδ»ñÅúÊÊÓ¦Ö¢ÓõÏÍþ¹ú¼Ê£¬Ò಻¶ÔÈκεÏÍþ¹ú¼ÊÆ·ºÍ/»òÊÊÓ¦Ö¢×÷ÍƼö¡£±¾ÎÄÖÐÉæ¼°µÄÐÅÏ¢½ö¹©²Î¿¼£¬Çë×ñ´ÓÒ½Éú»òÆäËûÒ½ÁÆÎÀÉúרҵÈËÊ¿µÄÒâ¼û»òÖ¸µ¼¡£Ò½ÁÆÎÀÉúרҵÈËÊ¿×÷³öµÄÈκÎÓëÖÎÁÆÓйصľö¶¨Ó¦¸ù¾Ý»¼ÕߵľßÌåÇé¿ö²¢×ñÕÕµÏÍþ¹ú¼ÊƷ˵Ã÷Êé¡£ÈçÐèÁ˽⹫˾ÈκβúÆ·¡¢Ò½ÁÆ»ò¼²²¡µÄÏà¹ØÐÅÏ¢£¬ÇëÎñ±Ø×ÉѯҽÁÆÎÀÉúרҵÈËÊ¿¡£

Ç°Õ°ÐÔ˵Ã÷

±¾ÐÂΟåÖ¼ÔÚÌṩ¹ØÓÚµÏÍþÖƵÏÍþ¹ú¼Ê¼¯ÍÅÓÐÏÞ¹«Ë¾¼°Æ丽Êô¹«Ë¾£¨°üÀ¨Æä×Ó¹«Ë¾£¬Í³³ÆΪ¡°µÏÍþÖƵÏÍþ¹ú¼Ê¡±£©µÄÐÅÏ¢¡£Ëü²»¹¹³É¶ÔµÏÍþÖƵÏÍþ¹ú¼Ê»òÈκÎͶ×ʽ¨ÒéµÄÐÅÏ¢Åû¶¡£±¾ÐÂΟå°üº¬µÄÐÅÏ¢¿ÉÄÜ°üÀ¨ÓëµÏÍþÖƵÏÍþ¹ú¼ÊÒµÎñºÍ²úÆ·Ç°¾°¡¢¼Æ»®¡¢ÐÅÄî¡¢Ô¤ÆںͲßÂÔÏà¹ØµÄÇ°Õ°ÐÔÉùÃ÷¡£ÕâЩÉùÃ÷ÊÇ»ùÓÚÍƲâÐÔ¼ÙÉèµÄÔ¤²â£¬²¢²»±£Ö¤Î´À´µÄ±íÏÖ¡£ËüÃÇÊܵ½ÖîÈç¿Æѧ¡¢ÉÌÒµ¡¢ÕþÖΡ¢¾­¼Ã¡¢²ÆÎñ¡¢·¨ÂÉÒòËØÒÔ¼°¾ºÕù»·¾³ºÍÉç»áÌõ¼þµÈ·çÏպͲ»È·¶¨ÐÔµÄÓ°Ï죬ÕâЩÒòËغܶ඼ÊǵÏÍþÖƵÏÍþ¹ú¼ÊÎÞ·¨¿ØÖÆÇÒÄÑÒÔÔ¤²âµÄ£¬Òò´Ëʵ¼Ê½á¹û¿ÉÄÜÓë´Ë´¦ËùÊöÓÐÏÔÖø²îÒ죬ÇÒ¹ýÈ¥µÄ֤ȯ¼Û¸ñÇ÷ÊƲ»Ó¦×÷ΪδÀ´ÐÐÇéµÄÖ¸µ¼¡£Òò´Ë£¬Í¶×ÊÕßÔÚʹÓÃÕâЩÐÅÏ¢½øÐÐͶ×ʾö²ßʱӦ½÷É÷ÐÐÊ¡£¡°ÖÂÁ¦ÓÚ¡±¡°Ô¤ÆÚ¡±¡°ÏàÐÅ¡±¡°Ô¤²â¡±¡°Òâͼ¡±¡°Ô¤¼Æ¡±¡°¿ÉÄÜ¡±¡°½«¡±¡°Ó¦¸Ã¡±¡°¼Æ»®¡±¡°¼ÌÐø¡±¡°Ä¿±ê¡±¡°¿¼ÂÇ¡±¡°¹À¼Æ¡±¡°Ö¸µ¼¡±¡°Ç±ÔÚ¡±¡°×·Çó¡±ÒÔ¼°ÓÚÈκÎδÀ´¼Æ»®¡¢Ðж¯»òʼþµÄÌÖÂÛÖÐʹÓõÄÀàËÆ´ÊÓïºÍÊõÓ¾ù±íʾǰհÐÔÉùÃ÷¡£µÏÍþÖƵÏÍþ¹ú¼Ê²»³Ðŵ»ò±£Ö¤Ç°Õ°ÐÔÐÅÏ¢µÄ׼ȷÐÔ¡¢¼°Ê±ÐÔ»òÍêÕûÐÔ£¬²¢ÇÒ²»³Ðµ£¸üлòÐÞ¶©ÕâЩǰհÐÔÉùÃ÷µÄÒåÎñ¡£ÎÞÂÛÊǵÏÍþÖƵÏÍþ¹ú¼Ê»¹ÊÇÆäÈκζ­Ê¡¢Ô±¹¤»ò´úÀíÈË£¬¾ù²»¶ÔÈκÎÖ¤Ã÷²»×¼È·»òÎÞ·¨ÊµÏÖµÄÇ°Õ°ÐÔÉùÃ÷¸ºÔð£¬Ò²²»¶ÔÒòÒÀÀµ±¾ÐÂΟåÖÐÌṩµÄÐÅÏ¢¶ø²úÉúµÄÈκÎËðʧ»òË𺦸ºÔ𣬰üÀ¨µ«²»ÏÞÓÚÖ±½Ó¡¢Å¼È»¡¢¼ä½Ó»ò³Í·£ÐÔµÄË𺦡£


¡¾ÍøÕ¾µØͼ¡¿¡¾sitemap¡¿